Ischemia Reperfusion Injury - Pipeline Review, H2 2015 Is Released Ischemia Reperfusion Injury - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ischemia Reperfusion Injury - Pipeline Review, H2 2015, provides an overview of the Ischemia Reperfusion Injurys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on latestage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemia Reperfusion Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Ischemia Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and 1
scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173365/ischemiareperfusion-injury-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173365/ischemia-reperfusion-injury-pipeline-review-h2-2015 Table of Contents
Introduction 7 Global Markets Direct Report Coverage 7 Ischemia Reperfusion Injury Overview 8 Therapeutics Development 9 Pipeline Products for Ischemia Reperfusion Injury - Overview 9 Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10 Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11 Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 14 Ischemia Reperfusion Injury - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Ischemia Reperfusion Injury - Products under Development by Companies 19 Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 21 Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 23 Alligator Bioscience AB 23 Angion Biomedica Corp. 24 Antipodean Pharmaceuticals, Inc. 25 Biomedica Management Corporation 26 Bolder Biotechnology, Inc. 27 Curatis Pharma GmbH 28 2
Enteris BioPharma, Inc. 29 Erimos Pharmaceuticals, LLC (Inactive) 30 Gilead Sciences, Inc. 31 Ischemix 32 Kowa Company, Ltd. 33 LG Life Science LTD. 34 Omeros Corporation 35 Opsona Therapeutics Limited 36 Peptinnovate Limited 37 Pharming Group N.V. 38 PledPharma AB 39 Prolong Pharmaceuticals 40 Proteo, Inc. (Inactive) 41 Prothix BV 42 Trophos SA 43 Zealand Pharma A/S 44 Ischemia Reperfusion Injury - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 49 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 ADC-1004 - Drug Profile 56 AM/AMBP-1 - Drug Profile 57 Annexin A-1 - Drug Profile 60
3
ANV-6L15 - Drug Profile 61 APP-103 - Drug Profile 62 BB-3 - Drug Profile 63 BBT-059 - Drug Profile 66 C1 esterase inhibitor (human) - Drug Profile 67 CMX-2043 - Drug Profile 72 CRX-526 - Drug Profile 74 Curaglutide - Drug Profile 75 danegaptide - Drug Profile 76 Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 78 EP-80317 - Drug Profile 79 GS-459679 - Drug Profile 80 KN-93 - Drug Profile 81 mangafodipir trisodium - Drug Profile 83 MG-53 - Drug Profile 84 mirococept - Drug Profile 86 MitoQ - Drug Profile 88 Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 90 Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology Drug Profile 91 Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 93 MTP-131 - Drug Profile 94 NBD Peptide - Drug Profile 96 NecX - Drug Profile 98 Neutrolide - Drug Profile 99 NP-202 - Drug Profile 101 Oligonucleotide for Oncology and Cardiovascular - Drug Profile 103
4
OMS-721 - Drug Profile 104 OPN-305 - Drug Profile 106 PAC-G31P - Drug Profile 108 PIN-201601 - Drug Profile 110 pitavastatin NP - Drug Profile 111 PRO-02 - Drug Profile 112 R-190 - Drug Profile 113 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 115 Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 116 Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 117 Recombinant Proteins for Ischemia Reperfusion Injury - Drug Profile 118 Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 119 Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 120 Sanguinate - Drug Profile 121 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 123 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 124 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 125 Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 126 Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 127 Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 128 SMTP-7 - Drug Profile 129 Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 130 Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 131 terameprocol - Drug Profile 132
5
tiprelestat - Drug Profile 134 TRO-40303 - Drug Profile 137 UCF-101 - Drug Profile 139 UWA-TAT - Drug Profile 140 Ischemia Reperfusion Injury - Recent Pipeline Updates 141 Ischemia Reperfusion Injury - Dormant Projects 160 Ischemia Reperfusion Injury - Discontinued Products 164 Ischemia Reperfusion Injury - Product Development Milestones 165 Featured News & Press Releases 165 Appendix 173 Methodology 173 Coverage 173 Secondary Research 173 Primary Research 173 Expert Panel Validation 173 Contact Us 173 Disclaimer 174"
Read More http://www.idatainsights.com/reports-landing-page.php?id=173365/ischemiareperfusion-injury-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 6
Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
7